AI in radiology: There’ll be an ‘app store’ for that

Radiology is the medical specialty most conducive to clinical AI applications. After all, the pre-AI technique of computer-aided detection has been used in mammography since 1998, for example. So it shouldn’t come as a surprise to find AI “app stores” rising in radiology.

The Harvard Business Review posted a piece looking at the development June 17.

Article co-authors Woojin Kim, MD, and Karen Holzberger, both executives with Nuance—which, it must be noted, is already in the “radiology app store” business—suggest that such AI marketplaces can serve two groups of stakeholders.

For doctors and hospitals, these marketplaces can offer one-stop shopping for an array of AI offerings. For AI developers, they can mean access to a well-defined target market and an end-user feedback channel.

“While AI marketplaces should foster widespread adoption of AI in radiology, they also have the potential to help alleviate radiologist burnout,” not least by improving the speed and quality of radiology reporting, Kim and Holzberger write.

“The recent emergence of AI marketplaces can accelerate the adoption of AI algorithms, helping to manage growing workloads while providing doctors with tools to improve diagnoses, treatments and, ultimately, patient outcomes.”

Read the whole thing:

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.